2024-10-012025-09-302025-09-30false07319691CRANWELL MEDICAL DEVELOPMENTS LIMITED2026-06-1886210falseiso4217:GBPxbrli:pure073196912024-09-30073196912025-09-30073196912024-10-012025-09-30073196912023-09-30073196912024-09-30073196912023-10-012024-09-3007319691bus:SmallEntities2024-10-012025-09-3007319691bus:AuditExempt-NoAccountantsReport2024-10-012025-09-3007319691bus:FullAccounts2024-10-012025-09-3007319691bus:PrivateLimitedCompanyLtd2024-10-012025-09-3007319691core:WithinOneYear2025-09-3007319691core:AfterOneYear2025-09-3007319691core:WithinOneYear2024-09-3007319691core:AfterOneYear2024-09-3007319691core:ShareCapital2025-09-3007319691core:SharePremium2025-09-3007319691core:RevaluationReserve2025-09-3007319691core:OtherReservesSubtotal2025-09-3007319691core:RetainedEarningsAccumulatedLosses2025-09-3007319691core:ShareCapital2024-09-3007319691core:SharePremium2024-09-3007319691core:RevaluationReserve2024-09-3007319691core:OtherReservesSubtotal2024-09-3007319691core:RetainedEarningsAccumulatedLosses2024-09-3007319691core:LandBuildings2025-09-3007319691core:PlantMachinery2025-09-3007319691core:Vehicles2025-09-3007319691core:FurnitureFittings2025-09-3007319691core:OfficeEquipment2025-09-3007319691core:NetGoodwill2025-09-3007319691core:IntangibleAssetsOtherThanGoodwill2025-09-3007319691core:ListedExchangeTraded2025-09-3007319691core:UnlistedNon-exchangeTraded2025-09-3007319691core:LandBuildings2024-09-3007319691core:PlantMachinery2024-09-3007319691core:Vehicles2024-09-3007319691core:FurnitureFittings2024-09-3007319691core:OfficeEquipment2024-09-3007319691core:NetGoodwill2024-09-3007319691core:IntangibleAssetsOtherThanGoodwill2024-09-3007319691core:ListedExchangeTraded2024-09-3007319691core:UnlistedNon-exchangeTraded2024-09-3007319691core:LandBuildings2024-10-012025-09-3007319691core:PlantMachinery2024-10-012025-09-3007319691core:Vehicles2024-10-012025-09-3007319691core:FurnitureFittings2024-10-012025-09-3007319691core:OfficeEquipment2024-10-012025-09-3007319691core:NetGoodwill2024-10-012025-09-3007319691core:IntangibleAssetsOtherThanGoodwill2024-10-012025-09-3007319691core:ListedExchangeTraded2024-10-012025-09-3007319691core:UnlistedNon-exchangeTraded2024-10-012025-09-3007319691core:MoreThanFiveYears2024-10-012025-09-3007319691core:Non-currentFinancialInstruments2025-09-3007319691core:Non-currentFinancialInstruments2024-09-3007319691dpl:CostSales2024-10-012025-09-3007319691dpl:DistributionCosts2024-10-012025-09-3007319691core:LandBuildings2024-10-012025-09-3007319691core:PlantMachinery2024-10-012025-09-3007319691core:Vehicles2024-10-012025-09-3007319691core:FurnitureFittings2024-10-012025-09-3007319691core:OfficeEquipment2024-10-012025-09-3007319691dpl:AdministrativeExpenses2024-10-012025-09-3007319691core:NetGoodwill2024-10-012025-09-3007319691core:IntangibleAssetsOtherThanGoodwill2024-10-012025-09-3007319691dpl:GroupUndertakings2024-10-012025-09-3007319691dpl:ParticipatingInterests2024-10-012025-09-3007319691dpl:GroupUndertakingscore:ListedExchangeTraded2024-10-012025-09-3007319691core:ListedExchangeTraded2024-10-012025-09-3007319691dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-10-012025-09-3007319691core:UnlistedNon-exchangeTraded2024-10-012025-09-3007319691dpl:CostSales2023-10-012024-09-3007319691dpl:DistributionCosts2023-10-012024-09-3007319691core:LandBuildings2023-10-012024-09-3007319691core:PlantMachinery2023-10-012024-09-3007319691core:Vehicles2023-10-012024-09-3007319691core:FurnitureFittings2023-10-012024-09-3007319691core:OfficeEquipment2023-10-012024-09-3007319691dpl:AdministrativeExpenses2023-10-012024-09-3007319691core:NetGoodwill2023-10-012024-09-3007319691core:IntangibleAssetsOtherThanGoodwill2023-10-012024-09-3007319691dpl:GroupUndertakings2023-10-012024-09-3007319691dpl:ParticipatingInterests2023-10-012024-09-3007319691dpl:GroupUndertakingscore:ListedExchangeTraded2023-10-012024-09-3007319691core:ListedExchangeTraded2023-10-012024-09-3007319691dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-10-012024-09-3007319691core:UnlistedNon-exchangeTraded2023-10-012024-09-3007319691core:NetGoodwill2025-09-3007319691core:IntangibleAssetsOtherThanGoodwill2025-09-3007319691core:LandBuildings2025-09-3007319691core:PlantMachinery2025-09-3007319691core:Vehicles2025-09-3007319691core:FurnitureFittings2025-09-3007319691core:OfficeEquipment2025-09-3007319691core:AfterOneYear2025-09-3007319691core:WithinOneYear2025-09-3007319691core:ListedExchangeTraded2025-09-3007319691core:UnlistedNon-exchangeTraded2025-09-3007319691core:ShareCapital2025-09-3007319691core:SharePremium2025-09-3007319691core:RevaluationReserve2025-09-3007319691core:OtherReservesSubtotal2025-09-3007319691core:RetainedEarningsAccumulatedLosses2025-09-3007319691core:NetGoodwill2024-09-3007319691core:IntangibleAssetsOtherThanGoodwill2024-09-3007319691core:LandBuildings2024-09-3007319691core:PlantMachinery2024-09-3007319691core:Vehicles2024-09-3007319691core:FurnitureFittings2024-09-3007319691core:OfficeEquipment2024-09-3007319691core:AfterOneYear2024-09-3007319691core:WithinOneYear2024-09-3007319691core:ListedExchangeTraded2024-09-3007319691core:UnlistedNon-exchangeTraded2024-09-3007319691core:ShareCapital2024-09-3007319691core:SharePremium2024-09-3007319691core:RevaluationReserve2024-09-3007319691core:OtherReservesSubtotal2024-09-3007319691core:RetainedEarningsAccumulatedLosses2024-09-3007319691core:NetGoodwill2023-09-3007319691core:IntangibleAssetsOtherThanGoodwill2023-09-3007319691core:LandBuildings2023-09-3007319691core:PlantMachinery2023-09-3007319691core:Vehicles2023-09-3007319691core:FurnitureFittings2023-09-3007319691core:OfficeEquipment2023-09-3007319691core:AfterOneYear2023-09-3007319691core:WithinOneYear2023-09-3007319691core:ListedExchangeTraded2023-09-3007319691core:UnlistedNon-exchangeTraded2023-09-3007319691core:ShareCapital2023-09-3007319691core:SharePremium2023-09-3007319691core:RevaluationReserve2023-09-3007319691core:OtherReservesSubtotal2023-09-3007319691core:RetainedEarningsAccumulatedLosses2023-09-3007319691core:AfterOneYear2024-10-012025-09-3007319691core:WithinOneYear2024-10-012025-09-3007319691core:Non-currentFinancialInstrumentscore:CostValuation2024-10-012025-09-3007319691core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-10-012025-09-3007319691core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-10-012025-09-3007319691core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-10-012025-09-3007319691core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-10-012025-09-3007319691core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-10-012025-09-3007319691core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-10-012025-09-3007319691core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-10-012025-09-3007319691core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-10-012025-09-3007319691core:Non-currentFinancialInstrumentscore:CostValuation2025-09-3007319691core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-09-3007319691core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-09-3007319691core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-09-3007319691core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-09-3007319691core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-09-3007319691core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-09-3007319691core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-09-3007319691core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-09-3007319691core:Non-currentFinancialInstrumentscore:CostValuation2024-09-3007319691core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-09-3007319691core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-09-3007319691core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-09-3007319691core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-09-3007319691core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-09-3007319691core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-09-3007319691core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-09-3007319691core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-09-3007319691bus:Director12024-10-012025-09-3007319691bus:Director22024-10-012025-09-30

CRANWELL MEDICAL DEVELOPMENTS LIMITED

Registered Number
07319691
(England and Wales)

Unaudited Financial Statements for the Year ended
30 September 2025

CRANWELL MEDICAL DEVELOPMENTS LIMITED
Company Information
for the year from 1 October 2024 to 30 September 2025

Directors

FOLWELL, Neil Richard
PEDDER-SMITH, Stephen Mark, Dr

Registered Address

The Medical Centre
Cranwell Road
Driffield
YO25 6UH

Registered Number

07319691 (England and Wales)
CRANWELL MEDICAL DEVELOPMENTS LIMITED
Statement of Financial Position
30 September 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets3197,800202,100
197,800202,100
Current assets
Debtors422,27416,477
Cash at bank and on hand10,9956,617
33,26923,094
Creditors amounts falling due within one year5(14,638)(10,619)
Net current assets (liabilities)18,63112,475
Total assets less current liabilities216,431214,575
Creditors amounts falling due after one year6(75,476)(78,313)
Net assets140,955136,262
Capital and reserves
Called up share capital120120
Revaluation reserve18,83818,838
Profit and loss account121,997117,304
Shareholders' funds140,955136,262
The financial statements were approved and authorised for issue by the Board of Directors on 18 June 2026, and are signed on its behalf by:
FOLWELL, Neil Richard
Director
Registered Company No. 07319691
CRANWELL MEDICAL DEVELOPMENTS LIMITED
Notes to the Financial Statements
for the year ended 30 September 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and/or the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Current taxation
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. The assets residual values, useful lives and depreciation methods are reviewed and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date. Gains and losses on disposal are determined by comparing the proceeds with the carrying amount and are recognised in the Income Statement Depreciation is provided on all tangible fixed assets as follows: Freehold property - 2% Straight line
Trade and other debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Trade and other creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Financial instruments
The company enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.
2.Average number of employees

20252024
Average number of employees during the year22
3.Tangible fixed assets

Land & buildings

Total

££
Cost or valuation
At 01 October 24215,000215,000
At 30 September 25215,000215,000
Depreciation and impairment
At 01 October 2412,90012,900
Charge for year4,3004,300
At 30 September 2517,20017,200
Net book value
At 30 September 25197,800197,800
At 30 September 24202,100202,100
4.Debtors: amounts due within one year

2025

2024

££
Other debtors22,27416,477
Total22,27416,477
5.Creditors: amounts due within one year

2025

2024

££
Bank borrowings and overdrafts2,3901,942
Taxation and social security2,9122,652
Other creditors6,4413,250
Accrued liabilities and deferred income2,8952,775
Total14,63810,619
The bank loan is secured by a legal mortgage over the company's property.
6.Creditors: amounts due after one year

2025

2024

££
Bank borrowings and overdrafts75,47678,313
Total75,47678,313
The bank loan is secured by a legal mortgage over the company's property.